Company: BDRX
Filing Date: 2025-12-11
Form Type: F-1/A
Source: 0001214659-25-017944
Chunk: 152

Company: Biodexa Pharmaceuticals Plc
Filing Date: 2025-12-11
Form: F-1/A
Chunk 152
---
,
expenses, losses, damages and liabilities incurred by him or her in performing his duties or the exercise of his or her powers or otherwise
in relation to such company. Generally, under the Companies Act, a company may not indemnify its directors against personal liability
covering: liability to the company in cases where the company sues the director (i.e., only liability to third parties can be the subject
of an indemnity); liability for fines for criminal conduct or fines imposed by a regulator; or other liabilities, such as legal costs,
in criminal cases where the director is convicted, or in civil cases brought by the company where the final judgment goes against the
director.

The Registrant has entered
into a deed of indemnity with each of its directors and officers. Except as prohibited by applicable law, these deeds of indemnity may
require the Registrant, among other things, to indemnify its directors and officers for certain expenses, including attorneys’ fees,
judgments, fines and settlement amounts incurred by such directors and officers in any action or proceeding arising out of their service
as a director or officer of the Registrant, or one of its subsidiaries, or arising out of the services provided to another company or
enterprise at the Registrant’s request.

Insofar as indemnification
for liabilities arising under the Securities Act of 1933, as amended, may be permitted to directors, officers or persons controlling us
pursuant to the foregoing provisions, we have been informed that in the opinion of the Securities and Exchange Commission such indemnification
is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

| Item 7. | Recent Sales of Unregistered Securities |

The following information
is furnished with regard to all securities issued by the registrant within the last three years that were not registered under the Securities
Act of 1933, as amended. Unless otherwise indicated below, the issuance of such shares was deemed exempt from registration requirements
of the Securities Act, of 1933, as amended, as such securities were offered and sold outside of the United States to persons who were
neither citizens nor residents of the United States, pursuant to Regulation S, or such sales were exempt from registration under Section
4(a)(2) of Securities Act of 1933, as amended and Rule 506 of Regulation D promulgated thereunder.

On August 3, 2022, we issued
warrants to purchase 16,666 Ordinary Shares to a certain institutional investor